Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Self-help Lifestyle Medicine for Insomnia

7 de enero de 2021 actualizado por: Fiona YY Ho, Chinese University of Hong Kong

Effect of a Self-help Smartphone-based Lifestyle Intervention in Reducing Insomnia Symptoms: A Randomized Controlled Trial

This study will examine the effects of a self-help smartphone-based multi-component lifestyle medicine intervention (LM) for alleviating insomnia symptoms in a Chinese population. Since a range of lifestyle factors are related to the pathogenesis and progression of insomnia, modifying different lifestyle factors simultaneously, such as diet, exercise, stress, and sleep which are empirically supported by previous reviews, may be effective to reduce insomnia symptoms (Reid et al., 2010; Vedaa et al., 2016). Traditional Chinese nutritional values will be integrated into the smartphone application to increase the acceptability towards the intervention. A prevalence study suggested that self-help interventions are preferred due to the potential stigmatization related to mental health interventions and the high cost of mental health services in Hong Kong (Lee, Tsang, & Kwok, 2007). Nonetheless, to date, only limited self-help interventions that target lifestyle medicine for sleep-related problems are available. Through this study, we aimed to promote evidence-based patient care and improve help-seeking behaviors and access to evidence-based lifestyle interventions for insomnia.

Descripción general del estudio

Estado

Desconocido

Condiciones

Intervención / Tratamiento

Descripción detallada

This study will be a randomized controlled trial on the effects of a self-help smartphone-based multi-component lifestyle medicine intervention for reducing insomnia symptoms in the Chinese population. Prior to all study procedures, eligible participants will be required to complete an online informed consent (with telephone support). Assuming an alpha error of 5%, a beta error rate of 20%, and a between-group effect size of 0.77 for the Insomnia Severity Scale (Ip et al., 2020), the final sample is 28 for both groups. With an estimation of 20% withdrawal, 70 eligible participants will be randomly assigned to either the smartphone-based multi-component lifestyle medicine intervention (LM group) or the waitlist control group (WL group) in a ratio of 1:1.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

70

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Sha Tin, Hong Kong
        • The Chinese University of Hong Kong

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Hong Kong residents
  • Aged ≥ 18 years
  • Have an Insomnia Severity Index (ISI) score ≥10, indicating at least sub threshold level of insomnia symptoms are present
  • Able to read Chinese and type in Chinese or English
  • Have an Internet-enabled mobile device (iOS or Android operating system)
  • Are willing to provide informed consent and comply with the trial protocol

Exclusion Criteria:

  • Current involvement in psychotherapy or unstable medication for sleep, depression, and/or anxiety
  • Beck Depression Inventory (BDI-II) Item 9 score of at least 2 indicating a current moderate suicidal risk that requires active crisis management (referral information to professional services will be provided to those with serious suicidal risk)
  • Are having unsafe conditions and are not recommended for exercise or a change in diet by physicians
  • Having major psychiatric, medical, or neurocognitive disorders that make participation infeasible or interfere with the adherence to the lifestyle modification
  • Other untreated sleep disorders, including narcolepsy, obstructive sleep apnoea (OSA), and restless leg syndrome (RLS)/periodic leg movement disorder (PLMD) based on the cut-off scores (≥ 7 on narcolepsy; ≥ 15 on OSA; ≥ 7 on RLS/PLMD) of individual sections in SLEEP-50
  • Shift work, pregnancy, work, family, or other commitments that interfere with regular night-time sleep patterns
  • Hospitalization

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Grupo de control de lista de espera
Los participantes en el grupo de control de la lista de espera recibirán la intervención después de la evaluación inmediata posterior al tratamiento.
Experimental: Lifestyle Medicine Group
Lifestyle intervention with components including exercise, diet, stress management, and sleep management
Lifestyle intervention with components including exercise, diet, stress management, and sleep management

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in the Insomnia Severity Index (ISI)
Periodo de tiempo: Baseline, immediately post-intervention, and 1-month post-intervention
ISI is a 7-item scale designed to evaluate perceived insomnia severity. Ratings on the 5-point Likert scale are obtained on the perceived severity of sleep-onset, sleep-maintenance, early morning awakening problems, satisfaction with current sleep pattern, interference with daily functioning, noticeably of impairment attributed to the sleep problem, and level of distress caused by the sleep problem.
Baseline, immediately post-intervention, and 1-month post-intervention

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Encuesta de desarrollo propio
Periodo de tiempo: Base
La encuesta autodesarrollada recopilará información que incluye datos demográficos (p. ej., edad, sexo, nivel de educación, sector laboral, estado civil y lugar de residencia), consumo de sustancias, índice de masa corporal (IMC), patrón de actividad y descanso y ritmos sociales, etc.
Base
Change in the Hospital Anxiety and Depression Scale (HADS)
Periodo de tiempo: Baseline, immediately post-intervention, and 1-month post-intervention
The HADS, a self-reporting questionnaire used for assessing the level of depressive and anxiety symptoms over the past week on a 4-point scale. The HADS consists of two parts: an anxiety subscale (HADS-A) and a depression subscale (HADS-D), both of which have seven items.
Baseline, immediately post-intervention, and 1-month post-intervention
Change in the Short Form (Six-Dimension) Health Survey (SF-6D)
Periodo de tiempo: Baseline, immediately post-intervention, and 1-month post-intervention
SF-6D is a preference-based single index measure of health. A six-digit number represents each SF-6D health state, each digit denotes the level of one of six SF-6D dimensions: physical functioning, role limitation, social functioning, bodily pain, mental health, and vitality.
Baseline, immediately post-intervention, and 1-month post-intervention
Change in the Health-Promoting Lifestyle Profile (HPLP II)
Periodo de tiempo: Baseline, immediately post-intervention, and 1-month post-intervention
The 52-item HPLPII is composed of a total scale and six subscales to measure behaviors in the theorized dimensions of health-promoting lifestyle: spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility, and stress management.
Baseline, immediately post-intervention, and 1-month post-intervention
Change in the Sheehan Disability Scale (SDS)
Periodo de tiempo: Baseline, immediately post-intervention, and 1-month post-intervention
SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
Baseline, immediately post-intervention, and 1-month post-intervention
Change in the Credibility-Expectancy Questionnaire (CEQ)
Periodo de tiempo: Baseline, immediately post-intervention, and 1-month post-intervention
The 6-item CEQ yielded ratings of treatment credibility, acceptability/satisfaction, and expectations for success.
Baseline, immediately post-intervention, and 1-month post-intervention
Change in the Pittsburgh sleep quality index (PSQI)
Periodo de tiempo: Baseline, immediately post-intervention, and 1-month post-intervention
Participants' subjective sleep disturbance over the past month will be assessed using PSQI. PSQI consists of 19 self-rating items that can be categorized into seven components, including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored on a 4-point Likert scale (0-3). The sum of the seven components results in a global score of 21. A high score indicates worse sleep quality.
Baseline, immediately post-intervention, and 1-month post-intervention
Change in the Consensus Sleep Diary (CSD-M)
Periodo de tiempo: Baseline, immediately post-intervention, and 1-month post-intervention
The standardized sleep diary records sleep time, wake time, perceived sleeping quality, use of hypnotics, etc. on a daily basis. Variables derived from the sleep diary include sleep onset latency (SOL), wake after sleep onset (WASO), total wake time (TWT), total sleep time (TST), sleep efficiency (SE), etc.
Baseline, immediately post-intervention, and 1-month post-intervention

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Anticipado)

1 de marzo de 2021

Finalización primaria (Anticipado)

1 de agosto de 2021

Finalización del estudio (Anticipado)

1 de octubre de 2021

Fechas de registro del estudio

Enviado por primera vez

7 de enero de 2021

Primero enviado que cumplió con los criterios de control de calidad

7 de enero de 2021

Publicado por primera vez (Actual)

11 de enero de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

11 de enero de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

7 de enero de 2021

Última verificación

1 de enero de 2021

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir